Seoul Pharma Statistics

Total Valuation

Seoul Pharma has a market cap or net worth of KRW 40.22 billion.

Market Cap	40.22B
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Seoul Pharma has 11.66 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	11.66M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+6.40%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	4.73M

Valuation Ratios

The trailing PE ratio is 38.19.

PE Ratio	38.19
Forward PE	n/a
PS Ratio	n/a
PB Ratio	1.03
P/TBV Ratio	2.36
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.24, with a Debt / Equity ratio of 1.35.

Current Ratio	1.24
Quick Ratio	0.90
Debt / Equity	1.35
Debt / EBITDA	n/a
Debt / FCF	-2.69
Interest Coverage	1.85

Financial Efficiency

Return on equity (ROE) is 5.12% and return on invested capital (ROIC) is 2.38%.

Return on Equity (ROE)	5.12%
Return on Assets (ROA)	1.99%
Return on Capital (ROIC)	2.38%
Revenue Per Employee	245.79M
Profits Per Employee	6.12M
Employee Count	172
Asset Turnover	0.85
Inventory Turnover	4.09

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -9.30% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-9.30%
50-Day Moving Average	3,645.30
200-Day Moving Average	3,650.58
Relative Strength Index (RSI)	48.32
Average Volume (20 Days)	17,634

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Seoul Pharma had revenue of KRW 42.28 billion and earned 1.05 billion in profits.

Revenue	42.28B
Gross Profit	21.70B
Operating Income	1.58B
Pretax Income	831.57M
Net Income	1.05B
EBITDA	n/a
EBIT	1.58B
Earnings Per Share (EPS)	n/a

Full Income Statement

Balance Sheet

The company has 3.19 billion in cash and 28.39 billion in debt, giving a net cash position of -25.21 billion or -2,162.00 per share.

Cash & Cash Equivalents	3.19B
Total Debt	28.39B
Net Cash	-25.21B
Net Cash Per Share	-2,162.00
Equity (Book Value)	21.04B
Book Value Per Share	3,339.71
Working Capital	3.86B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.35 billion and capital expenditures -13.90 billion, giving a free cash flow of -10.55 billion.

Operating Cash Flow	3.35B
Capital Expenditures	-13.90B
Free Cash Flow	-10.55B
FCF Per Share	-904.93

Full Cash Flow Statement

Margins

Gross margin is 51.33%, with operating and profit margins of 3.75% and 2.49%.

Gross Margin	51.33%
Operating Margin	3.75%
Pretax Margin	1.97%
Profit Margin	2.49%
EBITDA Margin	n/a
EBIT Margin	3.75%
FCF Margin	n/a

Dividends & Yields

Seoul Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	35.60%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	n/a
FCF Yield	-26.23%

Stock Splits

The last stock split was on April 12, 2004. It was a forward split with a ratio of 2.

Last Split Date	Apr 12, 2004
Split Type	Forward
Split Ratio	2

Scores

Seoul Pharma has an Altman Z-Score of 1.68. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.68
Piotroski F-Score	n/a